Jump to content

The American Journal of Psychiatry: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
promotional
 
(24 intermediate revisions by 19 users not shown)
Line 1: Line 1:
{{Infobox journal
{{Infobox journal
| title = American Journal of Psychiatry
| title = American Journal of Psychiatry
| cover = [[File:American-J-Psychiatry-2014-9-cover.png]]
| cover = American-J-Psychiatry-2014-9-cover.png
| editor = Robert Freedman
| editor = Ned H. Kalin
| discipline = [[Psychiatry]]
| discipline = [[Psychiatry]]
| abbreviation = Am. J. Psychiatry
| abbreviation = Am. J. Psychiatry
Line 10: Line 10:
| frequency = Monthly
| frequency = Monthly
| history = 1844–present
| history = 1844–present
| openaccess =
| openaccess =
| license =
| license =
| impact = 12.295
| impact = 18.112
| impact-year = 2014
| impact-year = 2020
| website = http://ajp.psychiatryonline.org/
| website = http://ajp.psychiatryonline.org/
| link1 = http://ajp.psychiatryonline.org/toc/ajp/current
| link1 = http://ajp.psychiatryonline.org/toc/ajp/current
| link1-name = Current Issue
| link1-name = Current issue
| link2 = http://ajp.psychiatryonline.org/loi/ajp
| link2 = http://ajp.psychiatryonline.org/loi/ajp
| link2-name = Online Archive of All Issues
| link2-name = Online archive of all issues
| JSTOR =
| JSTOR =
| OCLC = 1480183
| OCLC = 1480183
| LCCN = 22024537
| LCCN = 22024537
Line 26: Line 26:
| eISSN = 1535-7228
| eISSN = 1535-7228
}}
}}
The '''''American Journal of Psychiatry''''' is a monthly [[Peer review|peer-reviewed]] [[medical journal]] covering all aspects of [[psychiatry]] and the official journal of the [[American Psychiatric Association]].<ref name="AJP">
'''''The American Journal of Psychiatry''''' is a monthly [[Peer review|peer-reviewed]] [[medical journal]] covering all aspects of [[psychiatry]], and is the official journal of the [[American Psychiatric Association]].<ref name="AJP">
{{cite web
{{cite web
| url = http://ajp.psychiatryonline.org/about
| url = http://ajp.psychiatryonline.org/about
| title = About ''The American Journal of Psychiatry''
| title = About ''The American Journal of Psychiatry''
| accessdate = 2016-05-07
| access-date = 2021-07-12
| year = 2016
| year = 2021
| publisher = American Psychiatric Association}}
| publisher = American Psychiatric Association}}
</ref> The first volume was issued in 1844, at which time it was known as the ''American Journal of Insanity''. The title changed to the current form with the July issue of 1921.
</ref> The first volume was issued in 1844, at which time it was known as the ''American Journal of Insanity''. The title changed to the current form with the July issue of 1921.


According to the ''[[Journal Citation Reports]]'', the journal has a 2020 [[impact factor]] of 18.112.<ref name=WoS>{{cite book |date=2021-06-30 |chapter=American Journal of Psychiatry |title=2020 Journal Citation Reports |publisher=[[Clarivate]] |edition=Science |series=[[Web of Science]]|title-link=Journal Citation Reports }}</ref>
The Journal regularly publishes reports of pharmaceutical industry-sponsored clinical trial results of psychiatric drugs.

According to the ''[[Journal Citation Reports]]'', the journal has a 2014 [[impact factor]] of 12.295.<ref name="AJP"/>


==Ethical concerns==
==Ethical concerns==
Several complaints, including legal cases, have charged the ''American Journal of Psychiatry'' with being complicit in pharmaceutical industry corruption of clinical trial results.<ref>The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance' by Jureidini, Jon, Amsterdam, Jay, McHenry, Leemon, ''International Journal of Risk & Safety in Medicine''. 2016 28[1]:33-43.</ref> In a Department of Justice case against Forest Pharmaceuticals, Forest pled guilty to the charges of misbranding the drug Celexa (citalopram).<ref>United States v Forest Pharmaceuticals, Plea Agreement, September 15, 2010</ref> The Complaint in Intervention clearly identifies a 2004 ghostwritten article published in the ''American Journal of Psychiatry'' in the names of Wagner ''et al''<ref>Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psych 2004; 161 (6): 1079-1083.</ref> as a part of this illegal marketing of Celexa for pediatric depression.<ref>United States v Forest Pharmaceuticals, Complaint in Intervention p. 17. section 60.</ref> Since the ''American Journal of Psychiatry'' has refused requests to retract fraudulent articles, the scientific status of the journal is seriously questioned along with concerns about serving as a vehicle for illegal drug promotion.
Several complaints, including legal cases, have charged ''The American Journal of Psychiatry'' with being complicit in pharmaceutical industry corruption of clinical trial results.<ref>{{cite journal|doi=10.3233/JRS-160671|pmid=27176755|title=The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance|journal=International Journal of Risk & Safety in Medicine|volume=28|issue=1|pages=33–43|year=2016|last1=Jureidini|first1=Jon N.|last2=Amsterdam|first2=Jay D.|last3=McHenry|first3=Leemon B.|doi-access=free}}</ref> In a Department of Justice case against Forest Pharmaceuticals, Forest pleaded guilty to the charges of misbranding the drug [[Celexa]] (citalopram).<ref>United States v Forest Pharmaceuticals, Plea Agreement, September 15, 2010</ref> The Complaint in Intervention clearly identifies a 2004 ghostwritten article published in ‘’The American Journal of Psychiatry'' in the names of Wagner ''et al.''<ref>{{cite journal|pmid=15169696|year=2004|last1=Wagner|first1=K. D.|title=A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents|journal=The American Journal of Psychiatry|volume=161|issue=6|pages=1079–83|last2=Robb|first2=A. S.|last3=Findling|first3=R. L.|last4=Jin|first4=J.|last5=Gutierrez|first5=M. M.|last6=Heydorn|first6=W. E.|doi=10.1176/appi.ajp.161.6.1079|doi-access=}}</ref> as a part of this illegal marketing of Celexa for pediatric depression.<ref>United States v Forest Pharmaceuticals, Complaint in Intervention p. 17. section 60.</ref>


==See also==
==See also==
Line 51: Line 49:
* {{Official website|http://ajp.psychiatryonline.org/}}
* {{Official website|http://ajp.psychiatryonline.org/}}


{{DEFAULTSORT:American Journal of Psychiatry}}
[[Category:Psychiatry journals]]
[[Category:Psychiatry journals]]
[[Category:Monthly journals]]
[[Category:Monthly journals]]
[[Category:Publications established in 1844]]
[[Category:Academic journals established in 1844]]
[[Category:English-language journals]]
[[Category:English-language journals]]
[[Category:American Psychiatric Association]]
[[Category:American Psychiatric Association academic journals]]




Latest revision as of 12:00, 11 January 2024

American Journal of Psychiatry
DisciplinePsychiatry
SpracheEnglisch
Edited byNed H. Kalin
Publication details
Former name(s)
American Journal of Insanity
History1844–present
Publisher
FrequencyMonthly
18.112 (2020)
Standard abbreviations
ISO 4Am. J. Psychiatry
Indexing
CODENAJPSAO
ISSN0002-953X (print)
1535-7228 (web)
LCCN22024537
OCLC no.1480183
Links

The American Journal of Psychiatry is a monthly peer-reviewed medical journal covering all aspects of psychiatry, and is the official journal of the American Psychiatric Association.[1] The first volume was issued in 1844, at which time it was known as the American Journal of Insanity. The title changed to the current form with the July issue of 1921.

According to the Journal Citation Reports, the journal has a 2020 impact factor of 18.112.[2]

Ethical concerns

[edit]

Several complaints, including legal cases, have charged The American Journal of Psychiatry with being complicit in pharmaceutical industry corruption of clinical trial results.[3] In a Department of Justice case against Forest Pharmaceuticals, Forest pleaded guilty to the charges of misbranding the drug Celexa (citalopram).[4] The Complaint in Intervention clearly identifies a 2004 ghostwritten article published in ‘’The American Journal of Psychiatry in the names of Wagner et al.[5] as a part of this illegal marketing of Celexa for pediatric depression.[6]

See also

[edit]

References

[edit]
  1. ^ "About The American Journal of Psychiatry". American Psychiatric Association. 2021. Retrieved 2021-07-12.
  2. ^ "American Journal of Psychiatry". 2020 Journal Citation Reports. Web of Science (Science ed.). Clarivate. 2021-06-30.
  3. ^ Jureidini, Jon N.; Amsterdam, Jay D.; McHenry, Leemon B. (2016). "The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance". International Journal of Risk & Safety in Medicine. 28 (1): 33–43. doi:10.3233/JRS-160671. PMID 27176755.
  4. ^ United States v Forest Pharmaceuticals, Plea Agreement, September 15, 2010
  5. ^ Wagner, K. D.; Robb, A. S.; Findling, R. L.; Jin, J.; Gutierrez, M. M.; Heydorn, W. E. (2004). "A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents". The American Journal of Psychiatry. 161 (6): 1079–83. doi:10.1176/appi.ajp.161.6.1079. PMID 15169696.
  6. ^ United States v Forest Pharmaceuticals, Complaint in Intervention p. 17. section 60.
[edit]


Stub icon 1 Stub icon 2

This article about a psychiatry journal is a stub. You can help Wikipedia by expanding it.

See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page.

Retrieved from "https://en.wikipedia.org/w/index.php?title=The_American_Journal_of_Psychiatry&oldid=1194919022"